Related Experiment Video
Updated: Jun 7, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Abemaciclib and Letrozole in Metastatic Male Breast Cancer
Leon Schönfeld1, Christian Möhring1, Rouven Strobel1
1Department for Internal Medicine, Bundeswehr Central Hospital, Koblenz, Germany.
Background:
Male breast cancer is a very rare disease and only accounts for around 1% of all breast cancers. The treatment strategies are based on those used for breast cancer in women. So far, there is a lack of randomized data to support specific treatment modalities in men. To our knowledge, a therapeutic approach with a combination of letrozole and abemaciclib has not yet been described for a male patient with metastatic breast cancer.
Case Description:
Here, we report a case of a male patient with advanced metastatic breast cancer treated with a combination of letrozole and abemaciclib. The therapy was well tolerated with no reported side effects. The follow-up CT showed regression of the primary tumor mass and the lymph nodes and soft tissue metastases.
Conclusion:
In summary, this case report clearly shows the effectiveness of the therapeutic approach and should be discussed for the treatment of future patients.
Insights
This case report details the successful use of letrozole and abemaciclib combination therapy for metastatic male breast cancer. The treatment was well-tolerated and showed significant tumor regression, offering a new therapeutic option.
Area of Science:
- Oncology
- Endocrinology
Background:
- Male breast cancer is rare, comprising ~1% of all breast cancers.
- Treatment protocols are extrapolated from female breast cancer guidelines due to limited male-specific data.
- Novel therapeutic strategies for metastatic male breast cancer are needed.
Observation:
- A male patient with advanced metastatic breast cancer was treated with a combination of letrozole and abemaciclib.
- The therapeutic regimen was administered without any reported adverse events.
- Computed tomography (CT) scans revealed a reduction in the primary tumor and metastatic lesions.
Findings:
- The combination of letrozole and abemaciclib demonstrated significant efficacy in treating metastatic male breast cancer.
- The treatment was well-tolerated, indicating a favorable safety profile.
- Objective tumor response, including regression of primary and metastatic sites, was observed.
Implications:
- This case suggests that the combination of letrozole and abemaciclib is a viable and effective treatment option for metastatic male breast cancer.
- The findings warrant further investigation and discussion for clinical application in similar patient cases.
- This approach may offer a new therapeutic avenue for a rare and challenging malignancy.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:39Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
